Safety and immunogenicity of a SARS-CoV-2 mRNA vaccine (SYS6006) in minks, cats, blue foxes, and raccoon dogs

被引:2
作者
Huo, Hong [1 ,2 ]
Wang, Jinming [1 ]
Li, Chan [3 ]
Xiao, Shuang [1 ]
Wang, Han [1 ]
Ge, Jinying [1 ]
Zhong, Gongxun [1 ,2 ]
Wen, Zhiyuan [1 ,2 ]
Wang, Chong [1 ,2 ]
Lang, Qiaoling [3 ]
Chen, Lili [3 ]
Wang, Zilong [3 ]
Wang, Jinliang [1 ,2 ]
Wang, Xijun [1 ]
He, Xijun [2 ]
Guan, Yuntao [2 ]
Shuai, Lei [1 ,2 ]
Bu, Zhigao [1 ,2 ,4 ]
机构
[1] Chinese Acad Agr Sci, Harbin Vet Res Inst, State Key Lab Anim Dis Control & Prevent, Harbin, Peoples R China
[2] Chinese Acad Agr Sci, Harbin Vet Res Inst, Natl High Containment Lab Anim Dis Control & Preve, Harbin, Peoples R China
[3] CSPC Pharmaceut Grp Co Ltd, CSPC Zhongqi Pharmaceut Technol Shijiazhuang Co Lt, Shijiazhuang, Hebei, Peoples R China
[4] Yangzhou Univ, Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou, Peoples R China
基金
黑龙江省自然科学基金;
关键词
SARS-CoV-2; mRNA vaccine; safety; neutralizing antibody; susceptible animals; TRANSMISSION;
D O I
10.3389/fcimb.2024.1468775
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Minks, cats, and some other species of carnivores are susceptible of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and have a high risk of transmitting SARS-CoV-2 to humans. The development of animal vaccines can be an effective measure to protect animals against SARS-CoV-2 and reduce the potential risk of human infection. We previously developed a messenger ribonucleic acid (mRNA) vaccine SYS6006 that has been proven to be an efficient coronavirus disease 2019 (COVID-19) vaccine widely used in humans. Here, we further evaluated the safety and immunogenicity of SYS6006 as an animal COVID-19 vaccine candidate for SARS-CoV-2 susceptible animals or wild animals. SYS6006 was safe and immunogenic in mice and completely protected mice against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. SYS6006 was able to induce neutralizing antibodies against the SARS-CoV-2 wild-type, Delta, and Omicron BA.2 strain on day 7 after prime immunization, and two doses of immunization could enhance the neutralizing antibody responses and produce long-lasting potent antibodies for more than 8 months in minks and cats, blue foxes, and raccoon dogs, while all immunized animals had no abnormal clinical signs during immunization. These results provided here warrant further development of this safe and efficacious mRNA vaccine platform against animal COVID-19.
引用
收藏
页数:12
相关论文
共 50 条
[21]   Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials [J].
Lim, Hui Xuan ;
Arip, Masita ;
Yahaya, Abdul Aziz Al-Fattah ;
Jazayeri, Seyed Davoud ;
Poppema, Sibrandes ;
Poh, Chit Laa .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2021, 26 (11) :1286-1304
[22]   Immunogenicity and adverse events of SARS-CoV-2 vaccine in health workers [J].
Juarez, Vicente ;
Marina, Gabriela ;
Ramon, Claudia ;
Parentis, Mariangeles ;
Mamani, Lorena ;
Rua, Gustavo A. ;
Espindola, Maria E. Crespo ;
Buschiazzo, Emilio a. ;
Aciar, Mariana m. ;
Belbruno, Leila n. ;
Lecumberri, MARiA B. ;
Ralle, Ana c. ;
Murillo, Juan m. luna ;
Delgado, Lucia ;
Caceres, Ivanna miranda ;
Bonnal, Juan p. ;
Guzman, Valeria e. ;
Eddelcop, Bernardo a. .
MEDICINA-BUENOS AIRES, 2024, 84 (03) :496-504
[23]   Efficacy and safety of a novel multivalent mRNA vaccine against SARS-CoV-2 in experimental animals [J].
Min, Seung Eui ;
Gu, Eun-Young ;
Jang, Min Seong ;
Lee, Young-Ju ;
Han, Ji-Seok ;
Lee, Woo Ghil ;
Jeong, Seong In ;
Song, Ji Young ;
Lee, In-Chul ;
Kwon, Hyung-Jun ;
Ryu, Young-Bae ;
Ko, Kyong-Cheol ;
Min, Byung Sun ;
Kim, Yong-Bum ;
Han, Kang-Hyun .
SCIENTIFIC REPORTS, 2025, 15 (01)
[24]   Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population [J].
Intapiboon, Porntip ;
Seepathomnarong, Purilap ;
Ongarj, Jomkwan ;
Surasombatpattana, Smonrapat ;
Uppanisakorn, Supattra ;
Mahasirimongkol, Surakameth ;
Sawaengdee, Waritta ;
Phumiamorn, Supaporn ;
Sapsutthipas, Sompong ;
Sangsupawanich, Pasuree ;
Chusri, Sarunyou ;
Pinpathomrat, Nawamin .
VACCINES, 2021, 9 (12)
[25]   The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2 [J].
Jamous, Yahya F. ;
Alhomoud, Dalal A. .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
[26]   Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients [J].
Haller, Maria C. ;
Kaiser, Robert A. ;
Langthaler, Simon ;
Brandstetter, Clara ;
Apfalter, Petra ;
Kerschner, Heidrun ;
Cejka, Daniel .
TRANSPLANT INTERNATIONAL, 2022, 35
[27]   SARS-CoV-2 mRNA vaccine: Sometimes life needs a boost [J].
Lo, Carson Ka-Lok ;
Kumar, Deepali .
TRANSPLANT INFECTIOUS DISEASE, 2023,
[28]   Serological response to a single dose of a SARS-CoV-2 mRNA vaccine [J].
Ramos, Angelica ;
Cardoso, Maria Joao ;
Norton, Pedro ;
Sarmento, Antonio ;
Guimaraes, Joao Tiago .
JOURNAL OF VIROLOGICAL METHODS, 2021, 296
[29]   Does the SARS-CoV-2 mRNA vaccine damage the ovarian reserve? [J].
Yildiz, Elif ;
Timur, Burcu ;
Guney, Gurhan ;
Timur, Hakan .
MEDICINE, 2023, 102 (20) :E33824
[30]   Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV: A cross-sectional study [J].
Cai, Shaohang ;
Liao, Guichan ;
Yu, Tao ;
Gao, Qiqing ;
Zou, Lirong ;
Zhang, Huan ;
Xu, Xuwen ;
Chen, Juanjuan ;
Lu, Aili ;
Wu, Yingsong ;
Li, Baisheng ;
Peng, Jie .
JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (09) :4224-4233